Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.03−0.03 (-2.83%)
Close on Nov 18, 2026Market cap $103.35MP/E –Yield –
Cellectis operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was -$39.40M, down 271.4% from the year before. The highest annual figure on record is $22.99M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$39.40M | -271.4% |
| FY2024 | Dec 31, 2024 | $22.99M | – |
| FY2023 | Dec 31, 2023 | -$24.75M | – |
| FY2022 | Dec 31, 2022 | -$87.44M | – |
| FY2021 | Dec 31, 2021 | -$104.56M | – |
| FY2020 | Dec 31, 2020 | -$80.26M | – |
| FY2019 | Dec 31, 2019 | -$69.14M | – |
| FY2018 | Dec 31, 2018 | -$68.14M | – |
| FY2017 | Dec 31, 2017 | -$52.33M | – |
| FY2016 | Dec 31, 2016 | -$32.71M | -1010.9% |
| FY2015 | Dec 31, 2015 | $3.59M | – |
See a number that looks wrong?